





Cyanide Exposure in Firefighting: A Pathophysiology Perspective

Authors: Nicholas Bierman, Dayne Kramer, Monika Nikicicz, Chloe Wittersheim, Sarah Geraci, Olivia Neidigh-Lloyd, Angela Carrick, DO



Research Question

- What is the established safety profile of hydroxocobalamin (CyanoKit) in the treatment of suspected cyanide poisoning?
- What specific considerations of adverse drug reactions and diagnostic uncertainty often warrant caution against using it?

 delay treatment. This study evaluates the delay treatment of the delay treatment.




Methods

Fifteen articles were reviewed from the available literature, including case reports (n = 3), observational studies (n = 3), research articles (n = 1), systematic reviews (n = 2), non-systematic reviews (n = 6).

Introduction and Background:

Cyanide poisoning is a lethal risk in enclosed fires, yet rapid diagnosis remains difficult. CyanoKit is a safe, fast-acting antidote, but its high cost and diagnostic uncertainty often delay treatment. This study evaluates the safety profile of CyanoKit, focusing on adverse effects, access barriers, and its role in empirical treatment. By understanding cyanide's pathophysiology and identifying key clinical triggers, we aim to support timely, life-saving intervention—especially in high-risk populations like firefighters.



Adapted from Everett et al., 2020

Limitations

Lack of randomized trials: Ethical constraints limit studies to observational data, reducing generalizability.

Delayed diagnosis: Cyanide levels are not rapidly available; surrogate markers like high lactate may be confounded.

Challenges in burn victims: Vascular damage can delay or distort serum sampling, requiring reliance on clinical suspicion.

Treatment complications: Hydroxocobalamin can interfere with lab assays (e.g., creatinine, bilirubin, oximetry), complicating post-treatment monitoring.



Check out our references!



Conclusion

Hydroxocobalamin is the preferred antidote for empiric cyanide poisoning treatment, especially in emergency settings. Advantages: Rapid action, safe profile, and no risk of methemoglobinemia (unlike sodium nitrite).

Proposed clinical threscholds for safer

use (Sheckter & Mandell, 2022):

• GCS < 10

Lactate ≥ 10 mmol/L

Concerns: Overuse in unconfirmed cases may lead to unnecessary risks and supply shortages.

Future improvements: Point-of-care diagnostics (e.g., portable lactate sensors, biosensors) could allow more targeted use.

Current recommendations: Use structured clinical algorithms, assess high-risk exposures, and implement triage systems to guide treatment.